Connect with us


Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial



Combination reduced the risk of disease progression by 38% versus Tagrisso monotherapy, the current 1st-line global standard of care.

Positive results from the FLAURA2 Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to Tagrisso alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

These results were presented today in a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) (abstract #PL03).

Results showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso alone (based on a hazard ratio [HR] of 0.62; 95% confidence interval [CI] 0.49-0.79; p<0.0001). By investigator assessment, the combination extended median PFS by 8.8 months versus Tagrisso alone. PFS results from blinded independent central review (BICR) were consistent, showing Tagrisso plus chemotherapy extended median PFS by 9.5 months (based on HR of 0.62; 95% CI 0.48-0.80; p=0.0002). Importantly, a clinically meaningful PFS benefit was observed across all prespecified subgroups, including sex, race, type of EGFR mutation, age at time of diagnosis, smoking history and central nervous system (CNS) metastases status at baseline.

At the time of this analysis, the overall survival (OS) data were immature however, a favourable trend was observed for Tagrisso plus chemotherapy.

Pasi A. Jänne, MD, PhD, medical oncologist at Dana-Farber Cancer Institute and principal investigator for the FLAURA2 trial, said: “Patients received nearly nine additional months before their EGFR-mutated non-small cell lung cancer progressed as a result of the addition of chemotherapy to standard-of-care osimertinib, building on the strong efficacy we have already seen with osimertinib monotherapy. With these convincing data, patients may soon have a choice of two highly effective osimertinib-based treatment options in this advanced disease setting.” 

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “The compelling FLAURA2 results add to the extensive evidence supporting Tagrisso as the backbone therapy in EGFR-mutated non-small cell lung cancer and establish a new benchmark for progression-free survival in this setting. We look forward to bringing this potential treatment regimen to patients with advanced lung cancer to further delay disease progression, especially for patients with the greatest unmet need including those with central nervous system metastasis at diagnosis.”

Summary of results: FLAURA2

Safety results and discontinuation rates due to adverse events (AEs) were consistent with the established profiles of each medicine and no new safety concerns were reported. Grade 3 or higher AEs from all causes occurred in 64% of patients in the Tagrisso plus chemotherapy arm versus 27% in the Tagrisso monotherapy arm.


Lung cancer
Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths.Lung cancer is broadly split into NSCLC and small cell lung cancer.2 Each year, there are an estimated 2.2 million people diagnosed with lung cancer globally with 80-85% of patients diagnosed with NSCLC, the most common form of lung cancer.1-3 Approximately 70% of people are diagnosed with advanced NSCLC.4

Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.5-7 Patients with EGFRm NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) which blocks the cell-signalling pathways that drive the growth of tumour cells.8

FLAURA2 is a randomised, open-label, multi-centre, global Phase III trial in the 1st-line treatment of patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC. Patients were treated with Tagrisso 80mg once daily oral tablets in combination with chemotherapy (pemetrexed (500mg/m2) plus cisplatin (75mg/m2) or carboplatin (AUC5)) every three weeks for four cycles, followed by Tagrisso with pemetrexed maintenance every three weeks.

The trial enrolled 557 patients in more than 150 centres across more than 20 countries, including in the US, Europe, South America and Asia. This is the analysis of the primary endpoint of PFS. The trial is ongoing and will continue to assess the secondary endpoint of OS.

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system (CNS) metastases. Tagrisso (40mg and 80mg once-daily oral tablets) has been used to treat nearly 700,000 patients across its indications worldwide and AstraZeneca continues to explore Tagrisso as a treatment for patients across multiple stages of EGFRm NSCLC.

Tagrisso, the only targeted therapy to improve survival in both early- and late-stages of EGFRm NSCLC, is approved as monotherapy in more than 100 countries including in the US, EU, China and Japan. These include for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC (FLAURA), locally advanced or metastatic EGFR T790M mutation-positive NSCLC, and adjuvant treatment of early-stage (IB, II and IIIA) EGFRm NSCLC (ADAURA), where Tagrisso recently demonstrated a statistically significant and clinically meaningful OS benefit.

AstraZeneca also has several ongoing Phase III trials focused on earlier stages of lung cancer including a trial in the Stage IA2-IA3 adjuvant resectable setting (ADAURA2), and in the Stage III locally advanced unresectable setting (LAURA).

The Company is also researching ways to address tumour mechanisms of resistance through the SAVANNAH and ORCHARD Phase II trials, and the SAFFRON Phase III trial, which test Tagrisso plus savolitinib, an oral, potent and highly selective MET TKI, as well as other potential new medicines.

AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.

The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.

AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.

AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca.

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.


1.           World Health Organisation. International Agency for Research on Cancer. Lung Fact Sheet. Available at Accessed August 2023. 

2.           LUNGevity Foundation. Types of Lung Cancer. Available at Accessed August 2023. 

3.           Cheema PK, et al. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019;26(1):37-42. 

4.           Cancer.Net. Lung Cancer – Non-Small Cell: Statistics. Available at: Accessed August 2023.

5.           Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013:6;2800-12.

6.           Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27.

7.           Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013:66;79-89.

8.           Cross DA, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov. 2014;4(9):1046-1061.

Continue Reading
Click to comment

Leave a Reply

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *


YA Holding erhåller obligationsinnehavarnas godkännande för villkorsändringar i sitt befintliga obligationslån




YA Holding AB (publ) (“YA” eller “Bolaget”) meddelar att det skriftliga förfarandet som initierades den 13 september 2023 (det ”Skriftliga Förfarandet”) avseende vissa ändringar i villkoren för Bolagets seniora säkerställda hållbarhetslänkade företagsobligationer med ISIN SE0016831150 (“Obligationerna”) idag har avslutats.

Ett tillräckligt antal röster har erhållits för att uppnå kvorum och en tillräcklig majoritet av de deltagande obligationsinnehavarna har röstat för Bolagets begäran i enlighet med det Skriftliga Förfarandet. Obligationsinnehavarna har därmed godkänt villkorsändringarna som framgår av kallelsen till det Skriftliga Förfarandet.

Villkorsändringarna trädde ikraft idag kl. 15.00 i samband med att röstfristen löpte ut. De justerade villkoren för Obligationerna kommer att finnas tillgängliga på Bolagets hemsida. Villkorsändringarna framgår av kallelsen till det Skriftliga Förfarandet som finns tillgänglig på Bolagets hemsida.

Martin Modig, VD YA Holding AB (publ)

För pressfrågor, vänligen kontakta:
Alice Hedin, tillförordnad pressekreterare
Tel: +46 (0) 70 878 91 05

Continue Reading


Önskar du som aktieägare i Hamlet BioPharma AB information från bolaget via e-post?




Följande information har nyligen skickats ut via brev-post till aktieägare i Hamlet BioPharma:

Vill du ge oss din e-postadress för att få information från Hamlet BioPharma?

Vi vill från Hamlet BioPharma att så många aktieägare som möjligt ska nås av all information från Bolaget.

Hittills har det varit svårt för oss att nå alla, delvis på grund av olika informationspolicys hos era aktieförvaltare.

Via e-post skulle vi kunna skicka ut all information direkt till er.

Vi ber er därför att skicka oss er e-postadress till och godkänna att vi skickar information till din e-postadress.

Vi kommer att svara per mejl när vi får mejl från dig.

Du kan alltid besöka vår nya hemsida på och läsa mer om oss.”

För ytterligare information, vänligen kontakta

Catharina Svanborg, Styrelseordförande och grundare av Hamlet BioPharma, +46-709 42 65 49

Petter Segelman Lindqvist, CEO Hamlet BioPharma

Continue Reading


Inbjudan: Presentation av Sandviks rapport för tredje kvartalet 2023




Sandvik publicerar sin rapport för tredje kvartalet måndagen den 23 oktober 2023, cirka kl. 11.30.

En kombinerad webcast och telefonkonferens för investerare, analytiker och finansiell media kommer att hållas kl. 13.00. Rapporten presenteras i en webcast och telefonkonferens av Stefan Widing, VD och koncernchef samt av Cecilia Felton, ekonomi- och finanschef.

Presentationen kommer att sändas direkt på vår hemsida

Kontaktinformation för konferenssamtal:

SE: +46 (0) 8 505 100 31

UK: +44 (0) 207 107 06 13

US: +1 (1) 631 570 56 13

Från cirka kl. 12.30 återfinns presentationsmaterial på

Stockholm, 2 oktober 2023

Sandvik AB

För ytterligare information kontakta Louise Tjeder, chef för investerarrelationer, tel. 070-782 63 74 eller Johannes Hellström, Presschef, tel. 070 721 1008.

Sandvik är en global, högteknologisk industrikoncern som tillhandahåller lösningar som förbättrar produktivitet, lönsamhet och hållbarhet inom tillverknings-, gruv- och infrastrukturindustrierna. Vi ligger i framkant inom digitalisering och fokuserar på att optimera våra kunders processer. Vårt världsledande erbjudande inkluderar utrustning, verktyg, tjänster och digitala lösningar för skärande metallbearbetning, gruvdrift, bergavverkning, krossning och sortering. Koncernen hade 2022 omkring 40 000 medarbetare och intäkter på cirka 112 miljarder SEK i runt 150 länder i kvarvarande verksamheter.


Continue Reading


Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.